Reaction
Rebound Eczema reporting signals
As of the last recalculation, Rebound Eczema appears in 2,039 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is DUPILUMAB (PRR 2,925.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dupilumab | 2,010 | 2,925.0 | 2,937.4 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 22 | 9.7 | 9.7 |
| Crisaborole | 8 | 8.5 | 8.5 |
| Triamcinolone Acetonide | 22 | 7.3 | 7.3 |
| Clobetasol Propionate Ointment Usp, 0.05% | 7 | 7.0 | 7.0 |
| Clobetasol Propionate | 7 | 6.9 | 6.9 |
| Nemolizumab-Ilto | 4 | 3.2 | 3.2 |